Complete Filing Data
CN Healthy Food Tech Group Corp. reported Stockholders Equity of -$175.4 thousand for FY2022.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean CN Healthy Food Tech Group Corp. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Net Income Loss | $1.4M | -$308.8K | -$181.0K |
| Operating Income Loss | -$1.7M | -$309.0K | -$181.0K |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | $2.1M | -$309.0K | -$181.0K |
| Income Tax Expense Benefit | $746.5K | -$226.00 | |
| Nonoperating Income Expense | $3.8M | ||
| Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | |||
| Cash Withdrawn From Trust Account To Pay Franchise And Income Taxes | $3.3K | ||
| Revenues | |||
| Cost Of Revenue |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income Loss | $3.3M | $2.9M | $773.7K | $1.6M | $356.8K | $375.00 | -$137.1K | -$60.3K | -$104.5K |
| Operating Income Loss | $4.6M | -$671.5K | -$520.0K | $2.3M | -$238.4K | -$479.9K | -$137.1K | -$60.3K | -$104.5K |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | $4.7M | $82.3K | $233.0K | $2.3M | $660.0K | $684.5K | -$137.1K | -$60.3K | |
| Income Tax Expense Benefit | $1.4M | $146.2K | $149.2K | $743.6K | $178.0K | $211.1K | |||
| Nonoperating Income Expense | $139.2K | $753.8K | $752.9K | $13.2K | $898.4K | $1.2M | |||
| Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | $141.0K | $179.4K | $53.0K | $294.9K | -$35.1K | -$4.00 | |||
| Cash Withdrawn From Trust Account To Pay Franchise And Income Taxes | $167.7K | $3.3K | |||||||
| Revenues | $7.9M | $4.3M | |||||||
| Cost Of Revenue | $2.3M | $1.3M |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Stockholders Equity | -$175.4K | $5.6K | ||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | ||||
| Retained Earnings Accumulated Deficit | -$2.7M | -$200.4K | ||
| Liabilities Current | $861.6K | $847.0K | ||
| Liabilities And Stockholders Equity | $69.7M | $671.7K | ||
| Liabilities | $3.4M | $847.0K | ||
| Common Stock Value | $200.00 | $193.00 | ||
| Assets | $69.7M | $671.7K | ||
| Accrued Liabilities Current | $70.8K | $70.0K | ||
| Assets Current | $690.1K | |||
| Temporary Equity Carrying Amount Attributable To Parent | $69.0M | |||
| Temporary Equity Accretion To Redemption Value Adjustment | -$2.8M | -$7.7M | ||
| Marketable Securities Noncurrent | $69.0M | |||
| Deferred Underwriting Fee Payable | $2.5M | |||
| Remeasurement Of Common Stock Subject To Possible Redemption | $2.8M | $7.7M | ||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | -$656.5K | $657.0K | ||
| Accrued Offering Costs Current | $221.9K | |||
| Offering Costs Included In Accrued Offering Costs | $221.9K | $106.3K | ||
| Taxes Payable Current | ||||
| Marketable Securities Unrealized Gain Loss | ||||
| Loans Payable Current | ||||
| Change In Fair Value Of Overallotment Option Liability | -$11.1K | |||
| Accounts Payable Current | ||||
| Overallotment Liability | $11.1K | |||
| Accrued Offering Costs | $221.9K | $106.3K | ||
| Amortization Of Debt Discount Premium | -$11.3K | |||
| Notes Payable Current | ||||
| Cash And Cash Equivalents At Carrying Value |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $17.7M | $14.7M | $11.6M | $10.8M | $9.1M | $7.3M | $6.9M | $1.00 | -$477.4K | -$340.2K | -$279.9K |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $37.2M | $25.2K | $88.00 | $41.4M | $19.5M | $91.4K | $179.3K | $14.00 | |||
| Retained Earnings Accumulated Deficit | $11.0M | -$6.1M | -$4.9M | $4.0M | -$3.2M | -$3.0M | -$2.8M | ||||
| Liabilities Current | $38.2M | $72.4M | $3.4M | $39.9M | $1.5M | $1.2M | $1.1M | ||||
| Liabilities And Stockholders Equity | $56.2M | $73.3M | $73.6M | $50.8M | $71.8M | $71.0M | $70.4M | ||||
| Liabilities | $38.5M | $75.0M | $5.9M | $39.9M | $4.0M | $3.7M | $3.6M | ||||
| Common Stock Value | $5.2K | $197.00 | $197.00 | $4.8K | $197.00 | $197.00 | $197.00 | ||||
| Assets | $56.2M | $73.3M | $73.6M | $50.8M | $71.8M | $71.0M | $70.4M | ||||
| Accrued Liabilities Current | $540.7K | $361.3K | $400.2K | $309.8K | $187.2K | $213.5K | |||||
| Assets Current | $46.2M | $155.0K | $79.7K | $44.0M | $71.3K | $239.5K | $544.2K | ||||
| Temporary Equity Carrying Amount Attributable To Parent | $4.5M | $72.6M | $71.8M | $71.0M | $70.3M | $69.6M | |||||
| Temporary Equity Accretion To Redemption Value Adjustment | -$706.3K | -$667.0K | -$597.4K | ||||||||
| Marketable Securities Noncurrent | $2.4M | $73.2M | $73.6M | $72.8M | $71.7M | $70.8M | $69.9M | ||||
| Deferred Underwriting Fee Payable | $2.5M | $2.5M | $2.5M | $2.5M | $2.5M | ||||||
| Remeasurement Of Common Stock Subject To Possible Redemption | -$790.8K | -$597.4K | |||||||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | -$366.00 | -$477.7K | |||||||||
| Accrued Offering Costs Current | $75.0K | $75.0K | $75.0K | $115.0K | |||||||
| Offering Costs Included In Accrued Offering Costs | $68.8K | ||||||||||
| Taxes Payable Current | $895.5K | $746.3K | $576.7K | $388.9K | $210.9K | ||||||
| Marketable Securities Unrealized Gain Loss | $28.1K | -$33.1K | |||||||||
| Loans Payable Current | $229.8K | $229.8K | $229.8K | ||||||||
| Change In Fair Value Of Overallotment Option Liability | $11.1K | ||||||||||
| Accounts Payable Current | $2.1M | $217.7K | $273.7K | $585.3K | |||||||
| Overallotment Liability | |||||||||||
| Accrued Offering Costs | |||||||||||
| Amortization Of Debt Discount Premium | |||||||||||
| Notes Payable Current | $3.0M | $831.3K | $741.3K | $425.0K | |||||||
| Cash And Cash Equivalents At Carrying Value | $37.2M | $41.4M | $179.3K | $657.0K |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Net Cash Provided By Used In Operating Activities | -$1.0M | -$83.2K | |
| Net Cash Provided By Used In Investing Activities | -$226.4K | -$69.0M | |
| Net Cash Provided By Used In Financing Activities | $582.9K | $69.7M | |
| Payments Of Stock Issuance Costs | $141.9K | $115.8K | |
| Increase Decrease In Accounts Payable And Accrued Liabilities | $799.00 | $67.4K | |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | -$32.3K | $33.2K | |
| Increase Decrease In Accrued Income Taxes Payable | $746.3K | ||
| Increase Decrease In Prepaid Insurance | $42.2K | ||
| Increase Decrease In Accrued Offering Costs | -$5.0K | ||
| Payments To Acquire Investments | $229.8K | $69.0M | |
| Proceeds From Issuance Initial Public Offering | $69.0M | ||
| Increase Decrease In Accrued Liabilities | $329.4K | $799.00 | |
| Proceeds From Repayments Of Related Party Debt | -$1.0M | ||
| Proceeds From Related Party Debt | |||
| Proceeds From Issuance Of Private Placement | $2.5M | ||
| Proceeds From Notes Payable | $425.0K | ||
| Increase Decrease In Accounts Payable | $87.6K | ||
| Payments For Investment Of Cash Into Trust Account | $69.0M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|
| Net Cash Provided By Used In Operating Activities | -$409.3K | -$374.1K | |
| Net Cash Provided By Used In Investing Activities | -$62.1K | $3.3K | |
| Net Cash Provided By Used In Financing Activities | $471.0K | -$106.9K | |
| Payments Of Stock Issuance Costs | $75.0K | $106.9K | |
| Increase Decrease In Accounts Payable And Accrued Liabilities | $147.2K | $142.7K | $9.2K |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | $78.8K | -$7.2K | |
| Increase Decrease In Accrued Income Taxes Payable | $149.2K | $210.9K | |
| Increase Decrease In Prepaid Insurance | -$42.2K | $132.4K | |
| Increase Decrease In Accrued Offering Costs | |||
| Payments To Acquire Investments | $229.8K | ||
| Proceeds From Issuance Initial Public Offering | |||
| Increase Decrease In Accrued Liabilities | |||
| Proceeds From Repayments Of Related Party Debt | |||
| Proceeds From Related Party Debt | $229.8K | ||
| Proceeds From Issuance Of Private Placement | |||
| Proceeds From Notes Payable | $316.3K | ||
| Increase Decrease In Accounts Payable | |||
| Payments For Investment Of Cash Into Trust Account | -$3.3K |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2023 | FY2022 |
|---|---|---|
| Common Stock Shares Outstanding | 2.0M | 1.9M |
| Common Stock Shares Issued | 2.0M | 1.9M |
| Common Stock Shares Authorized | 50.0M | 50.0M |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 |
| Preferred Stock Shares Authorized | 1.0M | 1.0M |
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 |
| Temporary Equity Shares Outstanding | 6.9M | |
| Temporary Equity Redemption Price Per Share | $10.00 | |
| Weighted Average Number Of Shares Outstanding Basic | ||
| Weighted Average Number Of Diluted Shares Outstanding | ||
| Earnings Per Share Diluted | ||
| Earnings Per Share Basic |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|
| Common Stock Shares Outstanding | 52.2M | 2.0M | 2.0M | 47.7M | 2.0M | 2.0M | 2.0M |
| Common Stock Shares Issued | 52.2M | 2.0M | 2.0M | 47.7M | 2.0M | 2.0M | 2.0M |
| Common Stock Shares Authorized | 160.0M | 50.0M | 50.0M | 160.0M | 50.0M | 50.0M | 50.0M |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Preferred Stock Shares Authorized | 1.0M | 1.0M | 1.0M | 1.0M | 1.0M | 1.0M | |
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Temporary Equity Shares Outstanding | 422.0K | 6.9M | 6.9M | 6.9M | 6.9M | 6.9M | |
| Temporary Equity Redemption Price Per Share | $10.61 | $10.52 | $10.41 | $10.29 | $10.18 | $10.09 | |
| Weighted Average Number Of Shares Outstanding Basic | 47.7M | 47.7M | |||||
| Weighted Average Number Of Diluted Shares Outstanding | 47.7M | 47.7M | |||||
| Earnings Per Share Diluted | $0.07 | $0.04 | |||||
| Earnings Per Share Basic | $0.07 | $0.04 |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Operating Costs And Expenses | $1.7M | $309.0K | $181.0K |
| Investment Income Interest | $3.5M | ||
| Other Prepaid Expense Current | $33.2K | ||
| Prepaid Insurance | |||
| Stock Issued1 | $3.00 | $3.00 | |
| Gain Loss Related To Litigation Settlement | |||
| Payment Of Office Expenses Made By Sponsor | -$269.3K | -$113.6K | |
| Stock Issued During Period Value Sale Of Private Placement Warrants | $2.5M | ||
| Other Noncash Expense | $269.3K | ||
| Notes Issued1 | $632.3K | $508.0K | |
| Issuance Of Representative Shares | 4.00 | ||
| Adjustments To Additional Paid In Capital Warrant Issued | $43.5K | ||
| Adjustments To Additional Paid In Capital Stock Issued Issuance Costs | $275.7K | ||
| Adjustments To Additional Paid In Capital Mark To Market | $3.3M | ||
| Sale Of Stock Number Of Private Placement Warrants | $2.5M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Costs And Expenses | $671.5K | $520.0K | $290.8K | $238.4K | $479.9K | $137.1K | $60.3K | $104.5K | ||
| Investment Income Interest | $131.0K | $753.8K | $752.9K | $4.2K | $931.4K | $858.3K | ||||
| Other Prepaid Expense Current | $55.2K | $79.6K | $834.00 | $26.1K | $54.2K | $25.9K | ||||
| Prepaid Insurance | $42.2K | $42.1K | $87.3K | $132.4K | ||||||
| Stock Issued1 | $597.4K | |||||||||
| Gain Loss Related To Litigation Settlement | $295.0K | |||||||||
| Payment Of Office Expenses Made By Sponsor | ||||||||||
| Stock Issued During Period Value Sale Of Private Placement Warrants | ||||||||||
| Other Noncash Expense | $95.3K | |||||||||
| Notes Issued1 | $186.6K | |||||||||
| Issuance Of Representative Shares | ||||||||||
| Adjustments To Additional Paid In Capital Warrant Issued | ||||||||||
| Adjustments To Additional Paid In Capital Stock Issued Issuance Costs | ||||||||||
| Adjustments To Additional Paid In Capital Mark To Market | ||||||||||
| Sale Of Stock Number Of Private Placement Warrants |
Most recent annual filing with the SEC: February 21, 2025
Data sourced from SEC EDGAR public filings as of August 5, 2026.